Untreated HIV: Harmful even at high CD4 cell counts

The Lancet

Volumn 376, Issue 9738, 2010, Pages 306-308

  Bassett, Ingrid V ^a   Sax, Paul E ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; CLINICAL PRACTICE; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NOTE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; VIRUS HEPATITIS;

EID: 77955708298     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61033-1     Document Type: Note

References (15)

1. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study Lancet 2010 10.1016/S0140-6736(10)60932-4 published online July 16.
2. K Bhaskaran, O Hamouda, M Sannes for the CASCADE Collaboration Changes in the risk of death after HIV seroconversion compared with mortality in the general population JAMA 300 2008 51 59
3. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population J Acquir Immune Defic Syndr 46 2007 72 77
4. N Lohse, AB Hansen, G Pedersen Survival of persons with and without HIV infection in Denmark, 1995-2005 Ann Intern Med 146 2007 87 95
5. A van Sighem, L Gras, P Reiss, K Brinkman, F de Wolf Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals AIDS 24 2010 1527 1535
6. The Antiretroviral Therapy Cohort Collaboration Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries Int J Epidemiol 38 2009 1624 1633
7. R Gnavi, A Petrelli, M Demaria, T Spadea, Q Carta, G Costa Mortality and educational level among diabetic and non-diabetic population in the Turin Longitudinal Study: a 9-year follow-up Int J Epidemiol 33 2004 864 871
8. PT Katzmarzyk, I Janssen, CI Ardern Physical inactivity, excess adiposity and premature mortality Obes Rev 4 2003 257 290
9. SG Deeks, AN Phillips HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity BMJ 338 2009 a3172
10. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group Major clinical outcomes in antiretroviral therapy-naive participants and in those not receiving ART at baseline in the SMART study J Infect Dis 197 2008 1133 1144
11. J Neuhaus, B Angus, JD Kowalska Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV AIDS 24 2010 697 706
12. R Moh, C Danel, E Messou Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa AIDS 21 2007 2483 2491
13. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf Dec 1, 2009 (accessed July 7, 2010).
14. N Clumeck, A Pozniak, F Raffi the EACS Executive Committee European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults HIV Med 9 2008 65 71
15. INSIGHT Strategic Timing of Antiretroviral Therapy (START) http://insight.ccbr.umn.edu/start (accessed June 9, 2010).